A practical reference on Dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-24. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Tryptophan, arginine, cysteine and charged amino acids, like aspartic and glutamic acid, are poorly removed. ERAP1's trimming efficiency can also be influenced by the internal sequence of the peptide, with preferences for hydrophobic and positively charged residues.
== Further reading == Beck, M. T.; Kauffman, G. B. (1985). "COS and C3S2: The Discovery and Chemistry of Two Important Inorganic Sulfur Compounds". Polyhedron. 4 (5): 775–781. doi:10.1016/S0277-5387(00)87025-4. J. Elliott Campbell; Jürgen Kesselmeier; Dan Yakir; Joe A. Berry; Philippe Peylin; Sauveur Belviso; Timo Vesala; Kadmiel Maseyk; Ulrike Seibt; Huilin Chen; Mary E. Whelan; Timothy W. Hilton; Stephen A. Montzka; Max B. Berkelhammer; Sinikka T. Lennartz; Le Kuai; Georg Wohlfahrt; Yuting Wang; Nicola J. Blake; Donald R. Blake; James Stinecipher; Ian Baker; Stephen Sitch (2017). "Assessing a New Clue to How Much Carbon Plants Take Up". EOS. 98. doi:10.1029/2017EO075313. hdl:10871/31921. Svoronos P. D. N.; Bruno T. J. (2002). "Carbonyl sulfide: A review of its chemistry and properties". Industrial & Engineering Chemistry Research. 41 (22): 5321–5336. doi:10.1021/ie020365n.
=== Emerald Twilight and beyond === In Emerald Twilight, Hal Jordan is driven to insanity and becomes the villain Parallax following the destruction of his hometown Coast City. He attacks Boodikka, cuts off her right hand, and takes her power ring, leaving her for dead. Boodikka is later revealed to have survived, but has been placed in suspended animation by the Manhunters along with many other former Green Lanterns, with the Manhunters intending to harness their energy to create more advanced Manhunters. After being freed, Boodikka is shocked that she no longer has her hand, and appears to remember nothing past her encounter with Parallax. During a later confrontation with the Manhunters, Kreon is killed and his ring chooses Boodikka. She resumes her duties in the Green Lantern Corps, replacing her lost hand with a Lantern construct.
=== Physical methods === Heat treatment − Treating food with heat, such as blanching or roasting, de-naturates enzymes and destroys the reactants responsible for browning. Blanching is used, for example, in winemaking, tea processing, storing nuts and bacon, and preparing vegetables for freezing preservation. Meat is often partially browned under high heat before being incorporated into a larger preparation to be cooked at a lower temperature which produces less browning. Cold treatment − Refrigeration and freezing are the most common ways of storing food, preventing decay. The activity of browning enzymes, i.e., rate of reaction, drops in low temperatures. Thus, refrigeration helps to keep the initial look, color, and flavour of fresh vegetables and fruits. Refrigeration is also used during distribution and retailing of fruits and vegetables. Oxygen elimination − Presence of oxygen is crucial for enzymatic browning, therefore eliminating oxygen from the environment helps to slow down the browning reaction. Withdrawing air or replacing it with other gases (e.g., N2 or CO2) during preservation, such as in vacuum-packaging or modified atmosphere packaging, wine or juice bottling, using impermeable films or edible coatings, dipping into salt or sugar solutions, keeps the food away from direct contact with oxygen. Impermeable films made of plastic or other materials prevent food being exposed to oxygen in the air and avoid moisture loss.
Sources: en.wikipedia.org
I am who I am, and what I believe in and what my spirituality is about is that we're all in this together. That I think it is not a good thing to believe as human beings we can turn our backs on the suffering of other people ... and this is not Judaism, this is what Pope Francis is talking about, that we can't just worship billionaires and the making of more and more money. Life is more than that. In 2016, he disclosed that he had "very strong religious and spiritual feelings", adding, "My spirituality is that we are all in this together and that when children go hungry, when veterans sleep out on the street, it impacts me." Sanders does not regularly attend synagogue, and he does not refrain from working on Rosh Hashanah, as observant Jews do. He has attended yahrzeit observances in memory of the deceased, for the father of a friend, and in 2015 attended a Tashlikh, an atonement ceremony, with the mayor of Lynchburg on the afternoon of Rosh Hashanah. According to Richard Sugarman, his Jewish identity is "certainly more ethnic and cultural than religious." His wife is Roman Catholic, and he has often expressed admiration for Pope Francis, saying that "the leader of the Catholic Church is raising profound issues. It is important that we listen to what he has said." He has said he feels very close to Francis's economic teachings, describing him as "incredibly smart and brave". In April 2016, he accepted an invitation from Marcelo Sánchez Sorondo, an aide close to Francis, to speak at a Vatican conference on economic and environmental issues.
== Properties == Polymer-Protein nanoparticles not only contain the traditional properties of nanoparticles, but also have their own unique properties based on the properties of specific proteins. Because they are proteinaceous, they have high biocompatibility, biodegradability and biofunctionality. Protein-polymer bioconjugates which is the building block of Polymer-Protein hybrids exhibit a unique array of properties such as: light-switching effects, acoustic signal capture, thermal energy transfer, and magnetic signal response.
== Polymerization == Polypropylene glycol is produced by ring-opening polymerization of propylene oxide. The initiator is an alcohol and the catalyst a base, usually potassium hydroxide. When the initiator is ethylene glycol or water the polymer is linear. With a multifunctional initiator like glycerine, pentaerythritol or sorbitol the polymer branches out.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.